“Global Injectable Drugs Market Outlook 2024: Global Opportunity and Demand Analysis, Market Forecast, 2018-2024” presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and deal landscapes.
Top Leading Companies: Pfizer Inc., Johnson & Johnson, Novartis AG, Merck & Co. Inc., Baxter International Inc., Sanofi, GlaxoSmithKline Plc., AstraZeneca, GILEAD SCIENCES, Inc., Nova Nordisk A/S, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical.
Request a Sample Copy at: https://www.industrydataanalytics.com/request-sample-page.php?gturl=18959?source=mednewsledger&Mode=15
Global Injectable Drugs market can be categorized on following basis
Based on Product Type
o Conventional Therapeutics
o Complex Biologics
Essential points covered in Global Injectable Drugs Market 2018 Research are:-
- What will the market size and the growth rate be in 2024?
- What are the key factors driving the Global Injectable Drugs market?
- What are the key market trends impacting the growth of the Global Injectable Drugs market?
- What are the challenges to market growth?
- Who are the key vendors in the Global Injectable Drugs market?
- What are the market opportunities and threats faced by the vendors in the Global Injectable Drugs market?
- What are the key outcomes of the five forces analysis of the Global Injectable Drugs market?
Get Exclusive Discount on this Report at: https://www.industrydataanalytics.com/inquire-before-buy.php?gturl=18959?source=mednewsledger&Mode=15
This independent 287 pages report guarantees you will remain better informed than your competition. With over 200 tables and figures examining the Injectable Drugs market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2024.
Drugs which are introduced into body with syringe & needle as a medium is termed as Injectable drugs. Among all the approved drugs by Food & Drug Administration (FDA) available in U.S., 97% of medications & vaccines are administered through injections. Top Injectable drugs such as remicade, avastin neulasta, rituxan, etc. are most commonly used across the globe. In 2012, over 180,000 units of remicade were available per one million lives worldwide. Nowadays, increasing price of Injectable biotech products is a challenge for every commercial player in the United Sates. In 2010, approval of several cancer therapies by FDA has driven the cost of Injectable drugs up to 4.0%. However, Injectable drugs used for cancer treatment accounted for more than 50.0% of benefits of medical Injectable costs. Recent increase in commercial health plans is establishing attractive business opportunities for Injectable drugs in Europe and North America region. In 2012, more than 60% of population in the United States received medical benefits, which is extensively raising the demand of Injectable drugs in the region. Although, illegal use of Injectable drugs is expected to hamper the adoption rate of Injectable drugs across the globe. In 2012, Greece and the UK have 3.1% and nearly 10% of per 1000 population who were using Injectable drugs illegally. Spain, UK, France and Italy has higher rate of abusing medical drugs as compared to other European countries. Moreover, the U.S. and Canada have nearly 3.0% of population aged above 12 years are illegally using medical Injectable drugs. This is one of the major factors which are obstructing the Injectable drugs market. However, stringent drugs polices is likely to reduce the illegitimate use of Injectable drugs worldwide.
Geographically, this report is segmented into several key Regions, with Sales, revenue, Market Share (%) and Growth Rate (%) of Injectable Drugs in these regions 2018 to 2024 (forecast), covering North America, Latin America, Europe, Asia-Pacific, Middle East and Africa (MEA), Rest of World.
Browse Full Report at: https://www.industrydataanalytics.com/global-injectable-drugs-market-outlook-2024-global-opportunity-and-demand-analysis-market-forecast-2016-2024-18959-p.php?source=mednewsledger&Mode=15
Market Size and Forecast:
Global Injectable drugs market is anticipated to reach USD 513.5 billion by 2024 from value USD 272.7 billion in 2016, growing at a CAGR of 8.23% during the forecast period of 2016 to 2024. North America is the dominating region in global Injectable drugs market in 2016. Rising number of chronic health issues and increasing number of partnership between medical companies to provide high quality affordable drugs is boosting the demand of Injectable drugs in U.S. and Canada. North America valued 109.1 billion in 2016 and is expected to reach USD 184.9 billion by 2024.
Based on segmentation, complex biologics holds the largest share nearly 60.0% of global Injectable drugs market in 2016. Increase in number of new drugs rising demand for license approval for biologics and new drugs is accelerating the market of complex biologics segment. Vaccines and insulin segment is expected to witness notable growth with 20.0% and 10.0% share of Injectable drugs market over the forecast period.
Asia-Pacific region is expected to be the fastest growing region in Injectable drug market over the forecast period. Asia-Pacific region is expected to reach the value of USD 133.5 billion by the end of 2024, growing at a CAGR of 10.51 % over the forecast period. Rising health awareness and growing penetration of self injection technology in Japan, Singapore & China is boosting the demand of Injectable drugs in the region. Increasing number of diabetes population in emerging economies such as India & China is expected to witness significant growth during the time period of 2016-2024.
Europe was the second largest region for Injectable drugs market in 2015, owing to the popularity of self-Injectable drug technology in the region. Growing demand of hormone replacement & cancer therapies are driving the adoption rate of Injectable drugs in Italy, Germany, the UK, Spain and other European countries. Europe is the leading region in self injection technology due to low rate of penetration of pen injectors in North America region. Europe is projected to reach value USD 159.2 billion by 2024 from valued 87.3 billion in 2016.
Lack of proper medical facilities, low competition and less stringent regulatory framework related with approval on medical drugs and devices is anticipated to create attractive business opportunities for Injectable drugs in Latin America & Middle East & Africa. Latin America & Middle East & Africa together held 7.0% market share in global Injectable drug market in 2016. Saudi Arabia, Israel, Mexico, Brazil & Argentina are estimated to gain favorable opportunities for Injectable drugs in the forecast years.
Market Drivers and Challenges
Rise in per capita drug spending, increase in personal disposable income and patient awareness are key factors to drive the growth of global Injectable drugs market. Rising number of patients affected with chronic disease such as cancer and diabetes is likely to boost the demand for Injectable drugs worldwide. Operational improvement, medical benefits and reimbursement policies are also driving the Injectable drugs market.
Risk of re-operation or death, safety concerns of Injectable drugs and less patient compliance is restraining the expansion of Injectable drugs market.
Industrydataanalytics provides syndicated Market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. Industrydataanalytics has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
+1 (704) 266-3234 | mail to: email@example.com
Dr Nancy Miller has over 20 years experience as a educator and health practitioner. She has a B.S. from Lake Head University In Thunder Bay, and a Ph.D. in biology from the University of Guelph . Dr. Miller has worked as a special medical consultant for a major insurance provider before becoming a freelance health author and public speaker. There are several ways to contact Dr. Miller here.